Systemic exposure, tissue distribution, and disease evolution of a high solubility ciprofloxacin-aluminum complex in a murine model of septicemia induced by Salmonella enterica serotype enteritidis

Molecular Pharmaceutics

Volumn 10, Issue 2, 2013, Pages 598-605

  Breda, Susana Andrea ^a,b   Guzmán, Maria Laura ^a,b   Confalonieri, Alejandra ^c   González, Claudia ^c   Sparo, Monica ^c   Manzo, Ruben Hilario ^a,b   Bruni, Sergio Sánchez ^c   Olivera, Maria Eugenia ^a,b  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b Unidad de Investigación y Desarrollo en Tecnología Farmacéutica UNITEFA CONICET   (Argentina)

^c Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

Author keywords

biopharmaceutic classification system; disease evolution; fluoroquinolone complexes; infection model; pharmacodynamics; pharmacokinetics

Indexed keywords

ALUMINUM; CIPROFLOXACIN; CIPROFLOXACIN ALUMINUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE COURSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; FOLLOW UP; GRAM NEGATIVE SEPSIS; INTESTINE; KIDNEY PARENCHYMA; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERITIDIS; SALMONELLOSIS; SEROTYPE; SINGLE DRUG DOSE; STOICHIOMETRY; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ALUMINUM; ANIMALS; CIPROFLOXACIN; FLUOROQUINOLONES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SALMONELLA ENTERICA; SEPSIS;

EID: 84873328904     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300356a     Document Type: Article

References (54)

1. Word Health Organization. 17th WHO Model List of EssentialMedicines. http://www.who.int/medicines/publications/essentialmedicines/en/index.html (accessed April 2012).
2. Olivera, M. E.; Manzo, R. H.; Junginger, H.; Midha, K.; Shah, V.; Stavchansky, S.; Dressman, J.; Barends, D. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride J. Pharm. Sci. 2011, 100, 23-33
3. Breda, S. A.; Jimenez Kairuz, A. F.; Manzo, R. H.; Olivera, M. E. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives Int. J. Pharm. 2009, 371, 106-113
4. Drusano, G. L.; Standiford, H. C.; Plaisance, K.; Forrest, A.; Leslie, J.; Caldwell, J. Absolute oral bioavailability of ciprofloxacin Antimicrob. Agents Chemother. 1986, 30, 444-446 (Pubitemid 16017326)
5. Brunner, M.; Sta, H.; Moller, J. G.; Schrolnberger, C.; Erovic, B.; Hollenstein, U.; Zeitlinger, M.; Eichler, H. G.; Muller, M. Target site concentrations of ciprofloxacin after single intravenous and oral doses Antimicrob. Agents Chemother. 2002, 46, 3724-3730 (Pubitemid 35403243)
6. Hoffken, G.; Lode, H.; Prinzing, C.; Borner, K.; Koeppe, P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration Antimicrob. Agents Chemother. 1985, 27, 375-379 (Pubitemid 15144703)
7. Tartaglione, T. A.; Raffalovich, A. C.; Poynor, W. J.; Espinel-Ingroff, A.; Kerkering, T. M. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses Antimicrob. Agents Chemother. 1986, 29, 62-66 (Pubitemid 16155223)
8. Plaisance, K. I.; Drusano, G. L.; Forrest, A.; Bustamante, C.; Standiford, H. C. Effect of dose size on bioavailability of ciprofloxacin Antimicrob. Agents Chemother. 1987, 31, 956-958 (Pubitemid 17084062)
9. USP 33-NF 28. The United States Pharmacopeia: The National Formulary; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2010.
10. Firestone, B. A.; Dickason, M. A.; Tran, T. Solubility characteristics of three fluoroquinolone ophthalmic solutions in an in vitro tear model Int. J. Pharm. 1998, 164 (1) 119-128 (Pubitemid 28160104)
11. Eiferman, R. A.; Snyder, J. P.; Nordquist, R. E. Ciprofloxacin microprecipitates and macroprecipitates in the human corneal epithelium J. Cataract. Refract. Surg. 2001, 27 (10) 1701-1702 (Pubitemid 33020139)
12. De Benedetti, G.; Brancaccio, A. Corneal deposit of ciprofloxacin after laser assisted subepithelial keratomileusis procedure: a case report J. Ophthalmol. 2010, 2010, 296034
13. Madhavan, H. N.; Rao, S. K.; Joseph, P. R.; Sulochana, K. N. Antibacterial activity of the white precipitate formed on the corneal surface after treatment with ciprofloxacin ophthalmic solution Cornea 1999, 18 (5) 549-552 (Pubitemid 29416249)
14. Sweetman, S. C. Martindale. The Complete Drug Reference, 36 th ed.; Pharmaceutical Press: London, U.K., 2009.
15. Trissel, L. A. Handbook of Injectable Drug, 9 th ed.; Amercian Society of Hospital Pharmacists: Bethesda, MD, 1996.
16. Sarma, B.; Chen, J.; His, H. Y.; Myerson, A. S. Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals Korean J. Chem. Eng. 2011, 28, 315-322
17. Olivera, M. E.; Mazzieri, M. R.; Manzo, R. H. New pharmaceutical derivatives of fluoroquinolones. Hydrochlorides of aluminium complexes of ciprofloxacin and norfloxacin STP Pharma Sci. 2000, 10, 251-256 (Pubitemid 30409071)
18. Manzo, R. H.; Mazzieri, M. R.; Olivera, M. E. Preparación de complejos en estado sólido de clorhidratos de antimicrobianos fluoroquiolónicos (AMFQs) con aluminio. Argentinian Patent, AR007762B1, 2005.
19. Chattah, A. K.; GarroLinck, Y.; Monti, G.; Levstein, P.; Breda, S. A.; Manzo, R. H.; Olivera, M. E. NMR and IR characterization of the aluminium complexes of norfloxacin and ciprofloxacin fluoroquinolones Magn. Reson. Chem. 2007, 45, 850-859
20. Alovero, F. L.; Olivera, M. E.; Manzo, R. H. In vitro pharmacodynamic properties of a fluoroquinolone pharmaceutical derivative: hydrochloride of ciprofloxacin-aluminium complex Int. J. Antimicrob. Agents 2003, 21, 446-451 (Pubitemid 36511406)
21. Allemandi, D. A.; Alovero, F. L.; Manzo, R. H. Formulation of a neutral solution of ciprofloxacin upon complexation with aluminum Farmaco 1999, 54, 758-760 (Pubitemid 30009666)
22. Olivera, M. E.; Bistoni, A.; Anun, H.; Salinas, A.; Manzo, R. H. Ototopic ciprofloxacin in a glycerin vehicle for the treatment of acute external otitis Ear, Nose Throat J. 2004, 83, 625-630
23. Olivera, M. E.; Bistoni, A.; Anun, H.; Salinas, A.; Manzo, R. H. Ototopic ciprofloxacin in a glycerin vehicle for the treatment of acute external otitis Ear, Nose Throat J. 2004, 83, 638
24. Veldman, K.; Cavaco, L. M.; Mevius, D.; Veldman, K.; Cavaco, L. M.; Mevius, D.; Battisti, A.; Franco, A.; Botteldoorn, N.; Bruneau, M.; Perrin-Guyomard, A.; Cerny, T.; De Frutos Escobar, C.; Guerra, B.; Schroeter, A.; Gutierrez, M.; Hopkins, K.; Myllyniemi, A. L.; Sunde, M.; Wasyl, D.; Aarestrup, F. M.. International collaborative study on the occurrence of plasmid-mediated quinolone resistance in Salmonella enterica and Escherichia coli isolated from animals, humans, food and the environment in 13 European countries J. Antimicrob. Chemother. 2011, 66 (6) 1278-1286
25. Johnson, L. R.; Gould, L. H.; Dunn, J. R.; Berkelman, R.; Mahon, B. E. Foodnet travel working group, Salmonella infections associated with international travel: a foodborne diseases active surveillance network (FoodNet) study Foodborne Pathog. Dis. 2011, 8 (9) 1031-1037
26. Kim, S. Salmonella serovars from foodborne and waterborne diseases in Korea, 1998-2007: total isolates decreasing versus rare serovars emerging J. Korean Med. Sci. 2010, 25 (12) 1693-1699
27. Hendriksen, R. S.; Vieira, A. R.; Karlsmose, S.; Lo Fo Wong, D. M.; Jensen, A. B.; Wegener, H. C.; Aarestrup, F. M. Global monitoring of Salmonella serovar distribution from the World Health Organization Global Foodborne Infections Network Country Data Bank: results of quality assured laboratories from 2001 to 2007 Foodborne Pathog. Dis. 2011, 8 (8) 887-900
28. Guide to the care and use of experimental animals (Canadian Council on Animal Care), 1993.
29. Institutional Animal Care and Use Committee Guidebook (ARENA/OLAW IACUC Guidebook, National Institutes of Health, 2002.
30. Gonzalez, C.; Moreno, L.; Small, J.; Douglas, G.; Sanchez Bruni, S. F. A liquid chromatographic method, with fluorometric detection, for the determination of enrofloxacin and ciprofloxacin in plasma and endometrial tissue of mares Anal. Chim. Acta 2006, 569, 227-234 (Pubitemid 43286936)
31. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing; MIC Testing, Twelfth Informational Supplement (NCCLS); M100-S12; 22 (1), 2002.
32. Biswas, B.; Adhya, S.; Washart, P.; Trostel, A. N.; Powell, B.; Carlton, R.; Merril, C. R. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium Infect. Immun. 2002, 70 (1) 204-210 (Pubitemid 34028619)
33. Bakker-Woudenberg, I. A.; Schiffelers, R. M.; Storm, G.; Becker, M. J.; Guo, L. Long-circulating sterically stabilized liposomes in the treatment of infections Methods Enzymol. 2005, 391, 228-260 (Pubitemid 40254039)
34. Bakker-Woudenberg, I. A.; Ten Kate, M. T.; Guo, L.; Working, P.; Mouton, J. W. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats Antimicrob. Agents Chemother. 2001, 45 (5) 1487-1492 (Pubitemid 32374122)
35. Magallanes, M.; Dijkstra, J.; Fierer, J. Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis Antimicrob. Agents Chemother. 1993, 37 (11) 2293-2297 (Pubitemid 23324446)
36. Chono, S.; Tanino, T.; Seki, T.; Motrimoto, K. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects Drug Dev. Ind. Pharm. 2008, 34 (10) 1090-1096
37. Chono, S.; Suzuki, H.; Togami, K.; Motrimoto, K. Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections Drug Dev. Ind. Pharm. 2011, 37 (4) 367-372
38. Moazeni, E.; Gilani, K.; Sotoudegan, F.; Pardakhty, A.; Najafabadi, A. R.; Ghalandari, R.; Fazeli, M. R.; Jamalifar, H. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery J. Microencapsul. 2010, 27 (7) 618-627
39. Rashid, M.; Weintraub, A.; Nord, C. E. Comparative effects of the immediate and the extended release formulations of ciprofloxacin on normal human intestinal microflora J. Chemother. 2011, 23 (3) 145-149
40. Mirone, V.; Fusco, F.; Taglialatela, D.; Verze, P.; Di Vito, C.; Lotti, T.; Imbimbo, C.; Emeron, A. Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections J. Chemother. 2009, 21 (6) 651-660
41. Waugh, J.; Keating, G. M. Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis Drugs Aging 2004, 21 (1) 55-64 (Pubitemid 38186949)
42. Blondeau, J. M. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option Drugs 2004, 64 (6) 611-628 (Pubitemid 38482441)
43. Tanaka, M.; Kurata, T.; Fujisawa, C.; Ohshima, Y.; Aoki, H.; Okazaki, O.; Hakusui, H. Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide Antimicrob. Agents Chem. 1993, 37 (10) 2173-2178 (Pubitemid 23298207)
44. Sultana, N.; Arayne, S. M.; Hussain, F. In vitro monitoring of ciprofloxacin antacids interactions by UV & HPLC Pak. J. Pharm. Sci. 2005, 18 (4) 23-31
45. Harder, S.; Fuhr, U.; Beermann, D.; Staib, H. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the HF-capsule Br. J. Clin. Pharmacol. 1990, 30, 35-39 (Pubitemid 20225452)
46. Olivera, M. E.; Allemandi, D. A.; Manzo, R. H. Velocidad de disolución intrínseca y permeabilidad intestinal de complejos metálicos de norfloxacino y ciprofloxacino en relación a la formulación de comprimidos Acta Farm. Bon. 2000, 19 (3) 185-192
47. Bates, T. R.; Carrigan, P. J. Apparent absorption kinetics of micronized griseofulvin after its oral administration on single- and multiple-dose regimens to rats as a corn oil-in-water emulsion and aqueous suspension J. Pharm. Sci. 1975, 64 (9) 1475-1481
48. Colburn, W. A.; Di Santo, A. R.; Gibaldi, M. Pharmacokinetics of erythromycin on repetitive dosing J. Clin. Pharmacol. 1977, 17, 592-600 (Pubitemid 8197700)
49. Kaplan, S. A.; Weinfeld, R. E.; Abruzzo, C. W; Lewis, M. Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man J. Pharm. Sci. 1972, 61 (5) 773-778
50. Zal, O.; O'Reilly, T. Animal models in the evaluation of antimicrobial agents Antimicrob. Agents Chemother. 1991, 35, 1527-1531
51. Fu, K.; Lafredo, S.; Foleno, B.; Isaacson, D. M.; Barrett, J. F.; Tobia, A. J.; Rosenthale, M. E. In vitro and in vivo antibacterial activities of levofloxacin (l -ofloxacin), an optically active ofloxacin Antimicrob. Agents Chemother. 1992, 36, 860-866
52. Craig, W. Pharmacokinetic:pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men Clin. Infect. Dis. 1998, 26, 1-12 (Pubitemid 28068148)
53. Martinez, M.; McDermott, W. Pharmacology of the fluorquinolones: a perspective in domestic animals Vet. J. 2006, 172, 10-28 (Pubitemid 43869434)
54. Ma, H. H. M.; Chiu, F. C. K.; Li, R. C. Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations Pharm. Res. 1997, 14 (3) 366-370 (Pubitemid 27160952)